OR WAIT null SECS
© 2024 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2024 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Eldin Rammell is managing director at Rammell Consulting Ltd, a sub-contractor of Phlexglobal Ltd.
October 01, 2011
The past year has seen significant consolidation of mid-size CROs, with many of them being bought or put up for sale. In particular, the top six or seven CROs seem to be signing more preferred partner deals, such as Pfizer teaming with Parexel and ICON, and Takeda?s deals with Covance and Quintiles, which is driving mid-size CROs growth through major acquisitions.